Cortical involvement in four cases of primary lateral sclerosis using [11C]-flumazenil PET

Research output: Contribution to book/anthology/report/proceedingBook chapterResearchpeer-review

  • Martin R. Turner, The Radcliffe Infirmary
  • ,
  • Alexander Hammers, Hammersmith Hospital, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London
  • ,
  • Ammar Al-Chalabi, King's College London
  • ,
  • Christopher E. Shaw, King's College London
  • ,
  • Peter M. Andersen, Umeå University Hospital
  • ,
  • David J. Brooks
  • P. Nigel Leigh, King's College London

Four PLS patients underwent cerebral [11C]-flumazenil PET. They were compared firstly with a group of controls, then later directly with a group of sporadic ALS patients and a familial ALS group homozygous for the 'D90A' SOD1 gene mutation. There was a similar pattern of decreased binding in PLS patients when compared to controls as that seen in a previous study of sporadic ALS patients, supporting the concept that PLS is part of the same overall spectrum of MND. However, in direct group comparisons, both sporadic and homD90A ALS patients demonstrated relative decreases in anterior and orbito-frontal binding compared to PLS patients, suggesting that there may be differences in cortical vulnerability between phenotypic groups.

Original languageEnglish
Title of host publicationCortical involvement in four cases of primary lateral sclerosis using [11C]-flumazenil PET
Number of pages4
Publication year1 Aug 2007
Publication statusPublished - 1 Aug 2007
SeriesJournal of Neurology

    Research areas

  • Amyotrophic lateral sclerosis, D90A, Flumazenil, Positron emission tomography, Primary lateral sclerosis

See relations at Aarhus University Citationformats

ID: 130773318